Azitra (AZTR) Interest & Investment Income (2022 - 2026)
Azitra (AZTR) posted Interest & Investment Income of $14719.0 for Q1 2026, up 15.34% on a QoQ basis from $12761.0 in Q4 2025, and down 60.39% year-over-year from $37164.0 in Q1 2025.
Azitra (AZTR) Interest & Investment Income (2022 - 2026) Analysis & Trends
Azitra's Interest & Investment Income history runs 5 years deep, the most recent figure standing at $14719.0 for Q1 2026.
- Quarterly Interest & Investment Income fell 60.39% year-over-year to $14719.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $47764.0 (down 68.6% YoY) and the FY2025 annual result came in at $70209.0, down 42.71% from the prior year.
- Interest & Investment Income was $14719.0 for Q1 2026 at Azitra, up from $12761.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $51287.0 in Q4 2024 and bottomed at $264.0 in Q2 2023.
- A 5-year average of $13334.7 and a median of $6216.0 in 2024 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2024 — Interest & Investment Income surged 12950.13% — and 2025, when it sank 89.82%.
- Azitra's Interest & Investment Income stood at $762.0 in 2022, then sank by 48.43% to $393.0 in 2023, then jumped by 12950.13% to $51287.0 in 2024, then sank by 75.12% to $12761.0 in 2025, then advanced by 15.34% to $14719.0 in 2026.
- Business Quant data shows AZTR's Interest & Investment Income at $14719.0 in Q1 2026, $12761.0 in Q4 2025, and $4823.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Nanobiotix | 1,785.82 Bn | 1,785.76 Bn | - | - |
| 2 | Akari Therapeutics | 979.03 Bn | 979.03 Bn | - | - |
| 3 | BeOne Medicines | 472.82 Bn | 468.03 Bn | 1.35 Bn | 27.66 Mn |
| 4 | Vertex Pharmaceuticals | 123.92 Bn | 116.68 Bn | 2.59 Bn | 114.80 Mn |
| 5 | Regeneron Pharmaceuticals | 71.56 Bn | 62.81 Bn | 3.31 Bn | -65.80 Mn |
| 6 | Belite Bio | 62.00 Bn | 62.00 Bn | - | - |
| 7 | Argenx Se | 54.64 Bn | 49.45 Bn | 1.41 Bn | 48.00 Mn |
| 8 | Alnylam Pharmaceuticals | 37.84 Bn | 34.83 Bn | 959.66 Mn | 26.60 Mn |
| 9 | Revolution Medicines | 36.09 Bn | 36.09 Bn | - | 19.51 Mn |
| 10 | Azitra | 2.07 Mn | 2.07 Mn | - | 14,719.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14,719.00 |
| Dec 31, 2025 | 12,761.00 |
| Sep 30, 2025 | 4,823.00 |
| Jun 30, 2025 | 15,461.00 |
| Mar 31, 2025 | 37,164.00 |
| Dec 31, 2024 | 51,287.00 |
| Sep 30, 2024 | 47,389.00 |
| Jun 30, 2024 | 16,268.00 |
| Mar 31, 2024 | 7,609.00 |
| Dec 31, 2023 | 393.00 |
| Sep 30, 2023 | 634.00 |
| Jun 30, 2023 | 264.00 |
| Mar 31, 2023 | 285.00 |
| Dec 31, 2022 | 762.00 |
| Sep 30, 2022 | 3,201.00 |
| Jun 30, 2022 | 335.00 |